Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Acquires Dutch Oncology Target Company Semaia

NEW YORK, April 29 - Hybrigenics has acquired Dutch oncology target discovery company Semania, the companies said today.

 

The acquisition, in which Hybrigenics purchased 100 percent of Semaia's shares, enables Hybrigenics access to Semaia's oncology targets. These include therapeutic targets, both enzymes and cell surface proteins, in the Wnt pathway of colorectal cancer, and in the Ras-Raf and PKB/AKT pathways in other cancers.

 

Hybrigenics, of Paris, will use its yeast-two hybrid proteomics technology to explore the function of Semaia's targets and identify proteins that interact with these targets, the company said.

The company also said it expects the acquisition to "reinforce the international collaborations" it has with research institutes. Semaia, of Utrecht, was co-founded by Professors Hans Bos and Hans Clevers of the University of Utrecht. 

 

In the acquisition, Semiaia CEO Rian De Jonge will become Hybrigenics' executive vice president of R&D, and Bos and Clevers will join Hybrigenics' scientific advisory board.

 

Hybrigenics currently has drug discovery programs in cancer and in infectious diseases including HIV and Hepatitis C.

 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.